NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R33 Clinical Trial Required)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

Predicted deadline: Oct 2, 2023 (Full proposal)

Grant amount: Up to US $1,515,000

Funding uses: Research

Location of project: United States

Location of residency: United States

Overview:

NOTE: All applications are due by 5:00 PM local time of applicant organization.

The objective of this funding opportunity is to support investigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this FOA should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. If time and support for these and other pre-clinical and/or trial readiness activities are desired, applicants should consider the companion FOA which utilizes an R61/R33 phased approach.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.